Pseudoprogression has been recognized and widely accepted in the treatment of malignant gliomas, as transient increases in the volume of the enhanced area just after chemoradiotherapy, especially using temozolomide. We experienced a similar phenomenon in the treatment of malignant gliomas and meningiomas using boron neutron capture therapy (BNCT), a cell-selective form of particle radiation. He...

Combination cancer therapy (e.g., radiochemotherapy) is widely used to enhance the therapeutic effects and prevent recurrence of cancer. However, side monotherapy are also amplified when treating with combination therapy. A locally activated drug delivery strategy that can release payload in a tumor-selective manner greatly needed overcome Here, we explore potential combining boron neutron capt...

The purpose of this study was to evaluate the clinical outcome of boron neutron capture therapy (BNCT) and conventional treatment in patients with newly diagnosed glioblastoma. Since 1998 we treated 23 newly-diagosed GBM patients with BNCT without any additional chemotherapy. Their median survival time was 19.5 months; the 2-, 3-, and 5-year survival rates were 31.8%, 22.7%, and 9.1%, respectiv...

BACKGROUND Glioma stem cells in the quiescent state are resistant to clinical radiation therapy. An almost inevitable glioma recurrence is due to the persistence of these cells. The high linear energy transfer associated with boron neutron capture therapy (BNCT) could kill quiescent and proliferative cells. METHODS The present study aimed to evaluate the effects of BNCT on glioma stem/progeni...

Boron neutron capture therapy (BNCT) is a biologically targeted radiotherapy modality. So far, 249 cancer patients have received BNCT at the Finnish Research Reactor 1 (FiR 1) in Finland. The effectiveness and safety of radiotherapy are dependent on the radiation dose delivered to the tumor and healthy tissues, and on the accuracy of the doses. At FiR 1, patient dose calculations are performed ...

BNCT incorporates the targeting principles of chemotherapy and the anatomical localization principles of conventional radiotherapy but with three distinct advantages:  Current boron compounds at the required concentrations are non-toxic.  The time interval between drug administration and neutron irradiation can be chosen to maximize the concentration differential between tumour and normal tis...

The important things in designing facilities for BNCT are to obtain neutron beams with appropriate energy spectrum and intensity for efficient treatment. In recent years, at several universities, accelerator-based BNCT facilities were designed, which are composed of target and beam shaping assembly to generate epithermal neutron beams[1]. As a previous study, target system[2][3] and a beam shap...

We have proposed and validated the hamster cheek pouch model of oral cancer for boron neutron capture therapy (BNCT) studies and shown that boronophenylalanine delivers potentially therapeutic 36.9 +/- 17.5 ppm boron to tumor tissue with tumor:normal tissue and tumor:blood ratios of 2.4:1 and 3.2:1, respectively. Here we report the first evidence of the usefulness of BNCT for the treatment of o...